Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer HealthCare (Bayer) has expanded its collaboration with the Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard University to develop new therapies for cardiovascular disease leveraging insights from human genetics.
Subscribe to our email newsletter
Under the deal, Broad Institute and Bayer will collaborate on cardiovascular genomics, genetic discovery, target validation, and drug discovery activities.
A joint steering committee and joint research committee will be responsible for overseeing research progress and direction in this agreement.
Bayer HealthCare head of Global Drug Discovery and member of the Executive Committee professor Andreas Busch said: "We are excited to broaden our collaboration with the Broad Institute to the area of cardiovascular genomics to discover genes and mutational changes underlying cardiovascular disorders in order to develop new therapies and diagnostic options for these diseases.
"We have been collaborating over the last two years and have developed a very constructive partnership during this time."
Cardiovascular genomics uses genomic information to characterize disease risk and identify new therapeutic targets for drug discovery.